<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525212</url>
  </required_header>
  <id_info>
    <org_study_id>AI457-002</org_study_id>
    <nct_id>NCT01525212</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients</brief_title>
  <official_title>Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid
      (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype
      1a and 1b HCV infected subjects
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV RNA level on Day 4</measure>
    <time_frame>Within 4 days after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum decrease from baseline in plasma HCV RNA levels during the period from Day 1 to Day 28</measure>
    <time_frame>Days 1-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of the change from baseline in plasma HCV RNA levels and the time of maximum decrease during the period of Day 1 through Day 28</measure>
    <time_frame>Days 1-28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Days 1-28 (with SAE from screening to Day 30)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed plasma concentration (Cmin) of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein Binding (PB) of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 3 (0h and 2h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of free drug in plasma (fu) of BMS-929075 derived from plasma concentration versus time</measure>
    <time_frame>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between antiviral activity and measures of exposure to BMS-929075</measure>
    <time_frame>Days 1-6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-929075</intervention_name>
    <description>Oral Suspension, ≤ 25 mg, Once daily, 3 days</description>
    <arm_group_label>Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-929075</intervention_name>
    <description>Oral Suspension, ≤ 100 mg, Once daily, 3 days</description>
    <arm_group_label>Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-929075</intervention_name>
    <description>Oral Suspension, ≤ 400 mg, Once daily, 3 days</description>
    <arm_group_label>Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-929075</intervention_name>
    <description>Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days</description>
    <arm_group_label>Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-929075</intervention_name>
    <description>Oral Suspension, 0 mg, Once daily, 3 days</description>
    <arm_group_label>Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075</arm_group_label>
    <arm_group_label>Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075</arm_group_label>
    <arm_group_label>Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching BMS-929075</intervention_name>
    <description>Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days</description>
    <arm_group_label>Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, ages 18 to 65 years, inclusive

          -  Subjects who are naive to HCV treatment, defined as no previous exposure to an
             Interferon (IFN), Ribavirin (RBV); or any HCV-specific direct acting antiviral or
             experimental therapy

          -  HCV genotype 1a or 1b only

          -  HCV RNA viral load of ≥ 100,000 IU/mL

          -  Have one of the following: i) Documented Fibrotest score of ≤ 0.72 and AST to platelet
             ratio index (APRI) ≤ 2; or ii) Documented liver biopsy within 12 months preceding Day
             1 showing absence of cirrhosis

          -  Body Mass Index (BMI) of 18.0 to 35.0 kg/m2, inclusive

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of adrenal gland disease, including but not limited to adrenal insufficiency
             or Cushing's syndrome

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          -  Any major surgery within 4 weeks of study drug administration

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug

          -  Positive for hepatitis B surface antigen (HBsAg)

          -  Positive for Human Immunodeficiency Virus (HIV) -1 and/or -2 antibodies

          -  Smoking &gt; 10 cigarettes per day

          -  Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) &gt; 5x upper limit of
             normal (ULN)

          -  Total Bilirubin ≥ 1.5x ULN

          -  Hemoglobin &lt; 10 g/dL

          -  Platelets &lt; 75,000 cell/μL

          -  ALC (absolute lymphocyte count) &lt; 1000 cell/μL

          -  Creatinine clearance (as estimated by method of Cockcroft and Gault) less than 60
             mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

